Inovio Pharmaceuticals
INO
103 hedge funds and large institutions have $36.1M invested in Inovio Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 18 closing their positions.
2,477% more call options, than puts
Call options by funds: $4.54M | Put options by funds: $176K
80% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 15
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
3% more funds holding
Funds holding: 100 → 103 (+3)
5.52% less ownership
Funds ownership: 45.4% → 39.88% (-5.5%)
34% less capital invested
Capital invested by funds: $54.6M → $36.1M (-$18.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$1.01M |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$889K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$800K |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$568K |
| 5 |
BCM
Boxer Capital Management
San Diego,
California
|
+$563K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.05M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.02M |
| 4 |
Millennium Management
New York
|
-$729K |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$668K |
INO Hedge Fund Activity: Q2 2026 in Review
103 of the 8,286 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2026, worth a combined $36.1M — down 34% from $54.6M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new INO positions and 18 closed out — a net gain of 5 holders — while 27 added to existing stakes and 15 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $1.01M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $1.4M sold.
- 103 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2026, up from 100 in Q1 2026.
- Funds reported $36.1M of Inovio Pharmaceuticals stock for Q2 2026, down 34% quarter-over-quarter.
- 23 funds opened new Inovio Pharmaceuticals positions in Q2 2026 and 18 closed out, a net change of +5 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2026 was Two Sigma Investments, an estimated $1.01M added.
- The largest Inovio Pharmaceuticals seller in Q2 2026 was Adage Capital Partners, an estimated $1.4M sold.
Based on aggregated 13F filings for Q2 2026.